Amrix And Treanda Take-up Bodes Well For Cephalon
This article was originally published in The Pink Sheet Daily
Executive Summary
New drugs help firm move on from fading Actiq, beset by generic erosion.
You may also be interested in...
Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field
Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say
Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field
Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say
Price Hikes Protect Cephalon, Lining Up Nuvigil Ducks
Firm to add sales reps after ending Takeda co-promotion deal.